What is the recommended dosing regimen of secukinumab (Cosentyx) for an adult with psoriatic arthritis, including weight‑based dosing and options for severe disease?

Cosentyx Dosing for Psoriatic Arthritis

For adults with psoriatic arthritis, start Cosentyx (secukinumab) at 150 mg subcutaneously at weeks 0,1,2,3, and 4, then every 4 weeks thereafter; if the patient has coexistent moderate-to-severe plaque psoriasis, use 300 mg instead, and for patients with inadequate response to anti-TNF therapy, start directly at 300 mg. 1, 2

Standard Dosing Algorithm

Subcutaneous Administration (Primary Route)

Initial dose selection based on clinical presentation:

• PsA with moderate-to-severe plaque psoriasis: 300 mg at weeks 0,1,2,3,4, then every 4 weeks 1, 2

  • Given as one 300 mg injection OR two 150 mg injections

• PsA without significant skin involvement: 150 mg at weeks 0,1,2,3,4, then every 4 weeks 1, 2

  • Can be given with or without the loading regimen (weeks 0-4)
  • Without loading: 150 mg every 4 weeks from start

• Anti-TNF inadequate responders: 300 mg at weeks 0,1,2,3,4, then every 4 weeks 1

  • This higher dose is specifically recommended for this population

Dose escalation strategy:

• If patient continues to have active PsA on 150 mg, increase to 300 mg every 4 weeks 1, 2
• Evidence supports improved efficacy with dose escalation from 150 mg to 300 mg 3, 4

Intravenous Administration (Alternative Route)

For adults with PsA who prefer or require IV administration 2, 5, 6:

• With loading: 6 mg/kg IV at week 0, then 1.75 mg/kg IV every 4 weeks (maintenance)
• Without loading: 1.75 mg/kg IV every 4 weeks from start
• Administered as 30-minute infusion
• Maximum maintenance dose: Do not exceed 300 mg per infusion for the 1.75 mg/kg maintenance dose

The IV regimen was approved through model-informed drug development to match SC exposure profiles 6, 7. The 1.75 mg/kg maintenance dose provides steady-state exposure within the range of approved SC regimens.

Pediatric Dosing (Age ≥2 years with Juvenile PsA)

Weight-based subcutaneous dosing at weeks 0,1,2,3,4, then every 4 weeks 1, 2:

• ≥15 kg to <50 kg: 75 mg
• ≥50 kg: 150 mg

Key Clinical Considerations

Loading regimen benefits:

• The loading regimen (weeks 0,1,2,3,4) provides numerically higher and earlier responses for some high-hurdle endpoints compared to no loading 3
• Consider using loading regimen for patients requiring rapid disease control

When to use 300 mg over 150 mg:

1. Coexistent moderate-to-severe plaque psoriasis (mandatory) 1, 2
2. Anti-TNF inadequate responders (strongly recommended) 1
3. Inadequate response to 150 mg (dose escalation) 2
4. Meta-analysis shows 300 mg superior to 150 mg, especially in anti-TNF-IR patients 4

Response assessment:

• Consider discontinuation if no response after 16 weeks 1
• Primary efficacy typically assessed at week 16 5, 8
• Sustained improvements demonstrated through 52-104 weeks 3, 9

Important Safety Precautions

Before initiating treatment 2:

• Screen for active or latent tuberculosis (do not start with active TB)
• Complete age-appropriate vaccinations
• Avoid in patients with inflammatory bowel disease (can cause new cases or exacerbations) 1

Common pitfalls to avoid:

• Do not use in patients with active inflammatory bowel disease—secukinumab can worsen IBD 1
• Do not exceed 300 mg per infusion for IV maintenance dosing 2
• Avoid injection into areas with active psoriatic skin lesions 1

Combination therapy:

• May be administered with or without methotrexate 2

The evidence strongly supports secukinumab as effective therapy for PsA with ACR20 response rates of 50% at week 24 with both 150 mg and 300 mg regimens 8, and the safety profile remains consistent across dosing regimens with no significant increase in serious adverse events 4, 9.